+27 (0)83 440 0793 mark.fyvie@vxpharma.com
Select Page


VX Pharma is a clinical research organization that offers highly responsive, quick turnaround services through its dedicated trial site. As a fully integrated site, we are capable of offering end-to-end service delivery of clinical development across all phases of drug development. Our cutting-edge facilities, processes and clinical research expertise not only helps our clients develop products that work, but gets their product to market faster, saving them time and money.


VX Pharma came into being through the generous contribution of two seed capital investors, who remain minority shareholders to this day.

Dr. Fyvie continued to expand the team, joining forces with Dr. Gil Mahlati and Dr. Paul Abrahams in September 2011, making them major strategic shareholders in the business. In December 2011, acknowledging the company’s need to complete its infrastructure build and growth cycle, the Industrial Development Corporation (IDC) of South Africa invested significant venture capital thus allowing the business to build out a new state of the art facility and activate operations.

In early 2018 an investment deal was concluded with Ampath resulting in them becoming the majority shareholders in VX Pharma and allowing the business to consider its future growth strategy with a much broader vision.

First round of venture funding

IDC VC Round to Continuing the company’s expansion

Build out of site at the Innovation Hub

Operations commence

IDC exited via Ampath investment